Table 1 The clinical trials of novel immune checkpoint inhibitors in cancer immunotherapy

IMP321/Eftilagimod alpha (Immutep)

–

I

Metastatic RCC

NCT00351949

Completed

Paclitaxel

I

MBC

NCT00349934

Completed

Cyclophosphamide, fludarabine,

Melan-A VLP vaccine

I

Metastatic melanoma

NCT00324623

Completed

HLA-A2 peptides

I/II

Disease-free melanoma

NCT00365937

Terminated

Gemcitabine

I

Advanced pancreas cancer

NCT00732082

Terminated

Tumor antigenic peptides, montanide

I/II

Advanced melanoma

NCT01308294

Terminated

Paclitaxel

II

Metastatic breast cancer

NCT02614833

Active, not recruiting

Pembrolizumab

I

Metastatic melanoma

NCT02676869

Active, not recruiting

–

Advanced solid tumors

NCT03252938

Recruiting

Pembrolizumab

II

Advanced NSCLC and HNSCC

NCT03625323

Recruiting

Relatlimab /BMS-986016 (BMS)

Nivolumab

I/II

Advanced solid tumors

NCT01968109

Recruiting

Nivolumab

I

Advanced solid Tumors

NCT02966548

Recruiting

Nivolumab and Urelumab

I

Recurrent glioblastoma

NCT02658981

Recruiting

Nivolumab

I

Recurrent glioblastoma

NCT03493932

Recruiting

Nivolumab, Carboplatin,

Paclitaxel, Radiation

I

Gastro/esophageal cancer

NCT03044613

Recruiting

Nivolumab, Cabiralizumab, Ipilimumab, anti-GITR, IDO1 Inhibitor, Lirilumab, Radiation

I

Advanced solid tumors

NCT03335540

Recruiting

Nivolumab, Ipilimumab

I/II

Virus-associated tumors

NCT02488759

Recruiting

Nivolumab

I/II

Advanced hematologic malignancies

NCT02061761

Recruiting

Nivolumab, Ipilimumab, BMS-986205

I/II

Advanced solid tumors

NCT03459222

Recruiting

Nivolumab

II

Advanced chordoma

NCT03623854

Recruiting

Nivolumab

II

Metastatic melanoma

NCT03743766

Recruiting

Nivolumab

II

MSS advanced CRC

NCT03642067

Recruiting

Nivolumab

II

MSI-H solid tumors

NCT03607890

Recruiting

Nivolumab, Ipilimumab,

BMS-986205, BMS-813160

II

Advanced RCC

NCT02996110

Recruiting

Nivolumab, Ipilimumab, BMS-986205

II

Advanced GC

NCT02935634

Recruiting

Nivolumab, Dasatinib, Ipilimumab,

BMS- 986205

II

Advanced NSCLC

NCT02750514

Active, not recruiting

Ipilimumab, Nivolumab, Cobimetinib, Daratumumab, anti-LAG-3 antibody

II

Advanced CRC

NCT02060188

Active, not recruiting

Nivolumab, Ipilimumab

II

Melanoma

NCT02519322

Recruiting

LAG525 (Novartis)

PDR001

I/II

Advanced solid tumors

NCT02460224

Active, not recruiting

PDR001, NIR178, capmatinib,

MCS110, canakinumab

I

TNBC

NCT03742349

Recruiting

PDR001

II

Advanced solid and hematologic malignancies

NCT03365791

Active, not recruiting

PDR001, carboplatin

II

Advanced TNBC

NCT03499899

Recruiting

PDR001, capmatinib,

canakinumab, ribociclib

II

Advanced melanoma

NCT03484923

Recruiting

MK-4280 (Merck)

Pembrolizumab, Oxaliplatin, Irinotecan, Leucovorin, 5-FU, MK-4280A

I

Advanced solid tumors

NCT02720068

Recruiting

pembrolizumab

I/II

Hematological malignancies

NCT03598608

Recruiting

Pembrolizumab, Lenvatinib, MK-1308

II

Advanced NSCLC

NCT03516981

Recruiting

REGN3767 (Regeneron)

REGN2810

I

Advanced Cancers

NCT03005782

Recruiting

TSR-033 (Tesaro)

Anti-PD-1

I

Advanced solid tumors

NCT03250832

Recruiting

BI754111 (Bohringer Ingelheim)

BI754091

Early I

Neoplasms

NCT03433898

Recruiting

BI754091

I

Advanced cancers

NCT03156114

Recruiting

BI754091

I

Advanced NSCLC and HNSCC

NCT03780725

Recruiting

BI754091

II

Advanced solid tumors.

NCT03697304

Recruiting

BI754091, BI907828

I

Advanced solid tumors.

NCT03964233

Recruiting

Sym022 (Symphogen)

–

I

Advanced solid tumor or lymphomas

NCT03489369

Recruiting

Sym021, Sym023

I

Advanced solid tumor or lymphomas

NCT03311412

Recruiting

FS118^a (F-star)

–

I

Advanced malignancies

NCT03440437

Recruiting

MGD013^b (MacroGenics)

–

I

Advanced cancers

NCT03219268

Recruiting

TSR-022 (Tesaro)

TSR-042, TSR-033

I

Advanced solid tumors

NCT02817633

Recruiting

Niraparib, TSR-042, Bevacizumab,

Platinum-Based chemotherapy

I

Advanced solid tumors

NCT03307785

Recruiting

TSR-042

II

Liver Cancer

NCT03680508

Not yet recruiting

MBG453 (Novartis)

PDR001

I/II

Advanced malignancies.

NCT02608268

Recruiting

Decitabine, PDR001

I

AML or high risk MDS

NCT03066648

Recruiting

HDM201, Venetoclax

I

AML or high risk MDS

NCT03940352

Recruiting

Spartalizumab

I

GBM

NCT03961971

Not yet recruiting

Sym023 (Symphogen)

–

I

Advanced solid tumor or lymphomas

NCT03489343

Recruiting

Sym021, Sym022

I

Advanced solid tumor or lymphomas

NCT03311412

Recruiting

INCAGN2390 (Incyte)

–

I

Advanced malignancies

NCT03652077

Recruiting

LY3321367 (Eli Lilly and Company)

LY3300054

I

Advanced solid tumor

NCT03099109

Recruiting

LY3300054, Ramucirumab,

Abemaciclib, Merestinib

I

Advanced solid tumor

NCT02791334

Recruiting

BMS-986258 (BMS)

Nivolumab, rHuPH20

I/II

Advanced solid tumor

NCT03446040

Recruiting

SHR-1702 (Jiangsu HengRui)

Camrelizumab

I

Advanced solid tumor

NCT03871855

Not yet recruiting

RO7121661^c (Roche)

–

I

Advanced solid tumor

NCT03708328

Recruiting

MK-7684 (Merck)

Pembrolizumab

I

Advanced solid tumor

NCT02964013

Recruiting

Etigilimab /OMP-313 M32 (OncoMed)

Nivolumab

I

Advanced solid tumor

NCT03119428

Active, not recruiting

Tiragolumab/MTIG7192A/RG-6058 (Genentech)

Atezolizumab

I

Advanced solid tumor

NCT02794571

Active, not recruiting

Atezolizumab

II

Advanced NSCLC

NCT03563716

Active, not recruiting

BMS-986207 (BMS)

Nivolumab

I/II

Advanced solid tumor

NCT02913313

Recruiting

AB-154 (Arcus Biosciences)

AB122

I

Advanced malignancies

NCT03628677

Recruiting

ASP-8374 (Potenza)

Pembrolizumab

I

Advanced solid tumors

NCT03260322

Recruiting

–

I

Advanced solid tumor

NCT03945253

Not yet recruiting

JNJ-61610588 (Johnson & Johnson)

–

I

Advanced solid tumor

NCT02671955

Terminated

CA-170^d (Curis)

–

I

Advanced solid tumors and lymphomas

NCT02812875

Active, not recruiting

Enoblituzumab /MGA271 (MacroGenics)

–

I

Advanced solid tumors

NCT01391143

Active, not recruiting

Ipilimumab

I

Advanced solid tumors

NCT02381314

Completed

Pembrolizumab

I

Advanced solid tumors

NCT02475213

Active, not recruiting

–

I

Children with B7-H3-expressing solid tumors

NCT02982941

Completed

–

II

Prostate cancer

NCT02923180

Recruiting

MGD009^e (MacroGenics)

MGA012

I

Advanced solid tumors

NCT03406949

Recruiting

–

I

B7-H3-expressing tumors

NCT02628535

Recruiting

¹³¹I-8H9 /omburtamab (Y-mAbs)

–

I

DSRCT

NCT01099644

Recruiting

–

I

Advanced CNS or leptomeningeal cancer

NCT00089245

Recruiting

–

II/III

Neuroblastoma central nervous system/leptomeningeal metastases

NCT03275402

Recruiting

¹²⁴I-8H9 /omburtamab (Y-mAbs)

–

I

Gliomas

NCT01502917

Recruiting